CHM
Director Trades
| Date | Director | Value |
|---|---|---|
| P. Hopper | $800,000 | |
| P. Hopper | $50,000 | |
| P. Hains | $13,043 | |
| M. Prince | $14,956 |
Company News
Chimeric Therapeutics gains FDA fast-track approval for CHM CDH17 gastrointestinal cancer candidate
Chimeric Therapeutics (ASX: CHM) has received fast-track designation from the US Food and Drug Administration (FDA) for lead candidate CHM CDH17 to treat gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The FDA based its designation on the drug’s potential to improve outcomes for patients who have progressed beyond at least one prior line of therapy in the advanced […]
Chimeric Therapeutics receives ethics approval for CHM CDH17 gastrointestinal cancer trial
Chimeric Therapeutics (ASX: CHM) has received ethics approval for the initiation of a multi-site Phase 1/2 clinical trial of CHM CDH17 in patients with advanced gastrointestinal cancers. CHM CDH17 is a third generation novel CAR T cell therapy aimed at a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumours […]
Chimeric Therapeutics secures US patent for groundbreaking ‘killer cell’ cancer therapy
Australian cell therapy specialist Chimeric Therapeutics (ASX:CHM) has achieved another milestone in its efforts to commercialise its CHM 0201 (CORE-NK) “killer cell” technology. Chimeric has received confirmation from the US Patent & Trademark Office (USPTO) that it will allow the issuance of a patent application covering the CHM 0201 technology. CHM 0201 is used to […]
Australian biotech sector tipped for strong growth
Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it. International research firm KPMG recently forecast Australia could generate over $15 billion in exports to the United States and create 34,000 high-skilled jobs by accelerating US-Australia biotechnology collaboration. Australia’s $1.2b biotech industry currently ranks fifth in the world in terms […]
Chimeric Therapeutics highlights key cell therapy targets in treatment of various cancers
Chimeric Therapeutics (ASX: CHM) has reported strong progress for the 12 months to end December and highlighted key cell therapy targets for the coming year. Managing director Jennifer Chow cited positive Phase 1A data from a CHM 1101 trial into glioblastoma, clearance from the US Food and Drug Administration (FDA) for CHM 2101 to treat […]
Chimeric Therapeutics’ CHM 0201 and standard care drugs to transform AML treatment in new clinical study
Cell therapy company Chimeric Therapeutics (ASX: CHM) has confirmed the first patient in a Phase 1B clinical trial to treat acute myeloid leukemia (AML) has been dosed with CHM 0201 in combination with current standard of care drugs. The ADVENT-AML clinical trial is an investigator-initiated study currently open to enrolment at the MD Anderson Cancer […]
Chimeric Therapeutics sets new horizons in cell therapy for gastrointestinal and brain cancers
Clinical stage cell therapy company Chimeric Therapeutics (ASX: CHM) achieved significant success on a number of fronts during a highly-active quarter ending 31 December 2023. Most notably, the company obtained US Food and Drug Administration clearance for an investigational new drug application for its CHM 2101 novel third-generation CDH17 CAR T cell therapy for gastrointestinal […]
Chimeric Therapeutics begins innovative therapy trial for acute myeloid leukaemia
Australian cell therapy specialist Chimeric Therapeutics (ASX: CHM) has opened the door for enrolment in its international trial of a potential treatment for acute myeloid leukaemia (AML). The phase 1B ADVENT-AML clinical trial is to be conducted at the University of Texas (UT) MD Anderson Cancer Centre. It will evaluate Chimeric’s off-the-shelf universal donor NK […]
Chimeric Therapeutics set to trial groundbreaking AML cell therapy
Chimeric Therapeutics (ASX: CHM) has successfully completed the good manufacturing practice (GMP) test to support the company’s ADVENT-AML Phase 1B clinical trial. Under that trial, Chimeric’s off-the-shelf universal donor natural killer (NK) cell therapy will be evaluated in combination with standard-of-care therapy for patients with newly-diagnosed acute myeloid leukemia (AML). AML is a cancer of […]
Chimeric Therapeutics reports positive in vitro data for CHM 1301 on pancreatic and ovarian cancers
Chimeric Therapeutics (ASX: CHM) has announced positive data for next generation off-the-shelf cell therapy CHM 1301 in the treatment of ovarian and pancreatic cancers. The asset was used in pre-clinical in vitro models of both cancers and demonstrated “highly promising” efficacy. In the ovarian model, cell killing was shown to have increased by up to […]
